Drug intelligence / Profile preview

DX-110

Development stage: Preclinical
Lead developer: Delonix Bioworks
Modality: Vaccines & Immunotherapeutics

Overview

DX-110 is an experimental vaccine candidate being developed by Delonix Bioworks for the prevention of tuberculosis. It utilizes the company's proprietary OMV Plus platform, which leverages engineered outer membrane vesicles (OMVs) derived from bacteria. These vesicles are designed to serve as a delivery system for antigens, aiming to elicit a robust and protective immune response against *Mycobacterium tuberculosis*. The OMV Plus technology is intended to improve upon traditional vaccine approaches by enhancing antigen presentation and providing natural adjuvant properties. As of early 2024, DX-110 is in the lead optimization stage of preclinical development.

Beyond the preview

Go deeper on DX-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DX-110.

Explore the full profile